drugset / Trial / NCT05851365
Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer
Phase 0
Active not recruiting
1 enrolled
University of California, San Francisco
Bristol-Myers Squibb · collabU.S. Army Medical Research Acquisition Activity · collab
NaSingle-groupOpen-labelDiagnostic
Summary
This is a single site, prospective pilot study to determine the feasibility and safety of the administration of HP 13C bicarbonate in 10 patients with prostate cancer to determine potential hydrogen (pH) values in surrounding tissue. The proposed study will evaluate pre-surgical participants with histologically confirmed localized prostate cancer who receive infusion of hyperpolarized 13C injection prior to MR imaging with endorectal coil.
Timeline
- Start
- 2023-07-06
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hyperpolarized Bicarbonate (13C) | Diagnostic / imaging agent | 35 ml | Intravenous |